Standard BioTools switches Mass Cytometry sale to Element Biosystems for $5.5 million cash
Bitget2026/09/30 20:43- Standard BioTools replaced its prior Mass Cytometry divestiture deal with a definitive sale agreement to Element Biosystems.
- Element, an acquisition vehicle formed by GMT Venture Partners, will pay USD 5.5 million in cash at closing, subject to adjustments.
- The earlier agreement to sell the unit to Multiplex Bio was terminated after GMT Venture submitted an unsolicited proposal on Aug. 29, 2026.
- The revised terms lift net cash used in Treeline merger exchange-ratio calculations by about USD 15 million versus the Multiplex Bio deal.
- Closing is targeted by end-2026, substantially concurrent with the planned Treeline transaction, subject to stockholder approval and customary conditions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Broadcom (AVGO.US) syndicate begins raising 60 billions USD to supply chip "ammunition" for companies like Anthropic
According to informed sources, Broadcom's Wall Street syndicate is initiating the raising of $60 billion in new financing to purchase artificial intelligence (AI) chips, with beneficiaries including Anthropic PBC and other companies.
BICO completes integration of Cellenion into SCIENION, retires Cellenion brand
Japanese Yen draws support from hot Tokyo CPI as USD bulls await US NFP report
A global bond market sell-off sweeps across the world, pushing the dollar to a 17-month high; the euro becomes the hardest-hit currency.
On Friday, the US dollar hovered near a 17-month high and is set to rise for the third consecutive week.
Crypto prices
More
